An evaluation of shared vulnerabilities across all three synovial cell lines identified three compounds, the dual PI3K-mTOR inhibitor NVP-BEZ235, the PLK1 inhibitor BI 2536, and the BET bromodomain inhibitor JQ1 (Figure 6D), suggesting that targeting these pathways may have broad therapeutic utility in synovial sarcomas. The gene discussed is MTOR; the disease is synovial sarcoma.